Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

NeoSync Secures $13M in Financing to Fund Treatment Resistant Depression Technology Trial

By NeoSync | August 14, 2017

NeoSync, a clinical-stage company with a proprietary platform technology being used to develop advanced, non-invasive neuromodulation products, announced the completion of its Series D financing round, which included investment from Valiance Life Science Investments, as well as its original investor base totaling $13 million.

NeoSync plans to use the proceeds from this latest financing round to fund a registration trial using their proprietary NEST® technology in Treatment Resistant Depression. The investment will also accelerate the company’s efforts to prepare for future commercial release of this novel technology.

“This latest round of funding will allow us to execute remaining activities needed to gain regulatory clearance for our novel device,” said Kate Rumrill, President and CEO of NeoSync.  “We believe, once commercially available, our device will open up broader access to TMS, in a more convenient environment for patients.” 

“With its unique and innovative NEST® technology, NeoSync is well positioned to change the way TMS treatment is perceived and delivered,” said Jan Pensaert, founder and CEO of Valiance. “A home-use device is a very compelling proposition for patients suffering from depression and we are delighted to support NeoSync’s management team in their efforts to make their device a clinical and commercial success.”

About NEST® sTMS Technology 
NEST® (NeoSync-EEG Synchronized TMS) delivers low energy, alternating magnetic field stimulation in daily 30 minute sessions to gently adjust a depressed brain toward a more normal state.  Unique among TMS therapies, synchronized TMS (sTMS) used by NEST® is personalized to a patient’s individual alpha brain frequency, as measured by a brief electroencephalogram (EEG) recording.  NeoSync’s patented device design and configuration provides a unique ability to bring TMS therapy to a broader patient population with an at-home treatment option, under the care of their physician.

Related Articles Read More >

From solar system simulations to SaaS savings, how Codeium’s AI agent empowers non-coders and scientists alike
Aardvark AI forecasts rival supercomputer simulations while using over 99.9% less compute
Quantum Brilliance, Pawsey integrate room-temp quantum with HPC on NVIDIA GH200
Frontier supercomputer reveals new detail in nuclear structure
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE